Repurposing of Doramectin as a New Anti-Zika Virus Agent

Zika virus (ZIKV), belonging to the Flavivirus family and mainly transmitted by mosquitoes, causes a variety of adverse outcomes, including Guillain-Barré syndrome, microcephaly, and meningoencephalitis. However, there are no approved vaccines or drugs available for ZIKV. The discovery and research on drugs for ZIKV are still essential. In this study, we identified doramectin, an approved veterinary antiparasitic drug, as a novel anti-ZIKV agent (EC50 value from 0.85 μM to 3.00 μM) with low cytotoxicity (CC50 > 50 μM) in multiple cellular models. The expression of ZIKV proteins also decreased significantly under the treatment of doramectin. Further study showed that doramectin directly interacted with the key enzyme for ZIKV genome replication, RNA-dependent RNA polymerase (RdRp), with a stronger affinity (Kd = 16.9 μM), which may be related to the effect on ZIKV replication. These results suggested that doramectin might serve as a promising drug candidate for anti-ZIKV.

[1]  E. Atay,et al.  Investigation of developmental toxicity of favipiravir on fetal bone and embryonic development , 2022, Birth defects research.

[2]  Aili Gao,et al.  Doramectin inhibits glioblastoma cell survival via regulation of autophagy in vitro and in vivo , 2022, International journal of oncology.

[3]  S. Samrat,et al.  Antiviral Agents against Flavivirus Protease: Prospect and Future Direction , 2022, Pathogens.

[4]  Yongcheng Song,et al.  In vitro and in vivo characterization of erythrosin B and derivatives against Zika virus , 2021, Acta pharmaceutica Sinica. B.

[5]  H. Feldmann,et al.  Favipiravir (T-705) Protects IFNAR−/− Mice against Lethal Zika Virus Infection in a Sex-Dependent Manner , 2021, Microorganisms.

[6]  L. Kramer,et al.  JMX0207, a niclosamide derivative with improved pharmacokinetics, suppresses Zika virus infection both in vitro and in vivo. , 2020, ACS infectious diseases.

[7]  Haihe Wang,et al.  Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus , 2020, BMC Medicine.

[8]  D. Jans,et al.  The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro , 2020, Antiviral Research.

[9]  L. Kramer,et al.  Methylene blue is a potent and broad-spectrum inhibitor against Zika virus in vitro and in vivo , 2020, Emerging microbes & infections.

[10]  Wei Yang,et al.  Zika NS1–induced ER remodeling is essential for viral replication , 2019, The Journal of cell biology.

[11]  Lixia Yang,et al.  A Short Chemically Modified dsRNA-Binding PNA (dbPNA) Inhibits Influenza Viral Replication by Targeting Viral RNA Panhandle Structure. , 2019, Bioconjugate chemistry.

[12]  Rajanish Giri,et al.  Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease , 2018, ACS omega.

[13]  R. Hai,et al.  Structure and function of Zika virus NS5 protein: perspectives for drug design , 2018, Cellular and Molecular Life Sciences.

[14]  Richard J Kuhn,et al.  Zika Virus Structure, Maturation, and Receptors , 2017, The Journal of infectious diseases.

[15]  E. Matsubara,et al.  Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice , 2017, Antiviral Research.

[16]  Gengfu Xiao,et al.  Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses , 2017, Antiviral research.

[17]  R. Hai,et al.  The structure of Zika virus NS5 reveals a conserved domain conformation , 2017, Nature Communications.

[18]  B. Sankaran,et al.  Structure and function of the Zika virus full-length NS5 protein , 2017, Nature Communications.

[19]  P. Garcez,et al.  Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models , 2016, Viruses.

[20]  Doman Kim,et al.  Inhibitory effect of flavonoids against NS2B-NS3 protease of ZIKA virus and their structure activity relationship , 2016, Biotechnology Letters.

[21]  Xuping Xie,et al.  Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus , 2016, Open forum infectious diseases.

[22]  Christoph Nitsche,et al.  Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor , 2016, Science.

[23]  Wei Zheng,et al.  Drug combination therapy increases successful drug repositioning. , 2016, Drug discovery today.

[24]  Junchao Cai,et al.  Dengue Virus Subverts Host Innate Immunity by Targeting Adaptor Protein MAVS , 2016, Journal of Virology.

[25]  Werner Slenczka,et al.  Zika Virus Disease. , 2016, Microbiology spectrum.

[26]  Didier Musso,et al.  Zika Virus , 2016, Clinical Microbiology Reviews.

[27]  M. Diamond,et al.  Zika Virus: New Clinical Syndromes and Its Emergence in the Western Hemisphere , 2016, Journal of Virology.

[28]  A. Act,et al.  Zika Virus Infection in Pregnant Women in Rio de Janeiro - Preliminary Report. , 2016 .

[29]  Morgan Hennessey,et al.  Zika Virus Spreads to New Areas - Region of the Americas, May 2015-January 2016. , 2016, MMWR. Morbidity and mortality weekly report.

[30]  Dahai Luo,et al.  The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development. , 2015, Antiviral research.

[31]  Dahai Luo,et al.  A Crystal Structure of the Dengue Virus NS5 Protein Reveals a Novel Inter-domain Interface Essential for Protein Flexibility and Virus Replication , 2015, PLoS pathogens.

[32]  K. Kehn-Hall,et al.  Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. , 2013, Antiviral research.

[33]  L. Rubin,et al.  A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. , 2013, Cell stem cell.

[34]  A. Ryo,et al.  Establishment of a robust dengue virus NS3-NS5 binding assay for identification of protein-protein interaction inhibitors. , 2012, Antiviral research.

[35]  Alicia M. Hanson,et al.  Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. , 2012, The Journal of antimicrobial chemotherapy.

[36]  D. Harrich,et al.  Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus , 2012, The Biochemical journal.

[37]  Xiangjing Wang,et al.  Reversal of P‐glycoprotein‐mediated multidrug resistance in vitro by doramectin and nemadectin , 2010, The Journal of pharmacy and pharmacology.

[38]  H. Malet,et al.  The flavivirus polymerase as a target for drug discovery. , 2008, Antiviral research.

[39]  J. Ordóñez,et al.  Efficacy of doramectin in the protection of neonatal calves and post-parturient cows against field strikes of Cochliomyia hominivorax. , 1995, Veterinary parasitology.

[40]  K. Gration,et al.  Doramectin--a potent novel endectocide. , 1993, Veterinary parasitology.

[41]  C. Willhite,et al.  Teratogenic effects of ribavirin on hamster and rat embryos. , 1978, Teratology.

[42]  G. Dick,et al.  Zika virus. I. Isolations and serological specificity. , 1952, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[43]  Zhe Zhu,et al.  The FDA‐approved drug sofosbuvir inhibits Zika virus infection , 2017, Antiviral research.

[44]  J. Pérez-Santonja,et al.  Chapter-10 Antiparasitic Drugs , 2017 .